Dennis Mulroy Sells 15,725 Shares of AnaptysBio (NASDAQ:ANAB) Stock

by · The Markets Daily

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CFO Dennis Mulroy sold 15,725 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $44.85, for a total value of $705,266.25. Following the transaction, the chief financial officer owned 9,401 shares of the company’s stock, valued at $421,634.85. This trade represents a 62.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AnaptysBio Trading Up 4.0%

ANAB stock traded up $1.84 during trading on Thursday, hitting $47.53. The company had a trading volume of 416,584 shares, compared to its average volume of 693,419. The stock has a market cap of $1.32 billion, a PE ratio of -16.85 and a beta of 0.29. The business has a 50-day moving average of $38.13 and a 200-day moving average of $28.60. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $48.44.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. Research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has authorized a share buyback program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several research firms recently commented on ANAB. HC Wainwright decreased their target price on AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Barclays dropped their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wedbush restated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Finally, Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $55.40.

View Our Latest Report on AnaptysBio

Hedge Funds Weigh In On AnaptysBio

Large investors have recently bought and sold shares of the stock. US Bancorp DE grew its stake in shares of AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 979 shares in the last quarter. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares in the last quarter.

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

See Also